Progen Pharmaceuticals

Progen Pharmaceuticals (PGL)

Tue, 22/07/2008 - 22:46

Stock Code

PGL

Stock Exchange

Australian Securities Exchange

Progen Pharmaceuticals Limited (PGL) is a biotechnology company engaged in discovering, developing as well as commercialising the small molecule pharmaceutical for cancer treatment. PGL was listed on the Australian Stock Exchange on the 22nd of December 1995. Its average annual revenue reaches approximately $2.6 million out of its issued capital of $63 million. Its headquarters is located in Queensland, Australia and to date; around 40 people are employed in the company.

Progen Pharmaceuticals (PGL): Loser

Sat, 21/04/2007 - 07:03

Progen Pharmaceuticals closed the week 19 per cent lower and is the worst performing stock on the Australian sharemarket last week after some trial results for its liver cancer drug.

Syndicate content

Free Email Subscription to Share Trading

 My Share Trading Feed